ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      AI Subscribe Login/Register Profile Icon
      S&P 500
      5,718.57
      0.28%
      US Tech 100
      19,312.80
      0.08%
      Dow Jones
      42,124.65
      0.15%
      Brent Oil
      74.08
      0.47%
      Bitcoin
      63,217.09
      -0.17%
      Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. Aptinyx Inc (APTX) Quote

      Aptinyx Inc

      Aptinyx Inc (APTX)

      NASDAQ
      0.061
      0.00
      (0.00%)
      Closed September 24 4:00PM
      Delayed by 15 minutes
      0.00
      0.00
      (0.00%)
      After Hours: -
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      0.061
      Bid
      0.0811
      Ask
      0.0849
      Volume
      -
      0.00 Day's Range 0.00
      0.061 52 Week Range 0.061
      Previous Close
      0.061
      Open
      -
      Last Trade
      Last Trade Time
      Average Volume (3m)
      -
      Financial Volume
      -
      VWAP
      -

      Ask ADVFN Intelligence (AI)

      APTX Latest News

      More News

      Form 8-K - Current report

      December 21 2023
      Edgar (US Regulatory)

      Aptinyx Reports on Fourth Quarter and Full Year 2022 Results and Highlights and Review of Strategic Alternatives

      Aptinyx Inc. (Nasdaq: APTX) today reported recent business updates and financial results for the fourth quarter and full year 2022. Recent Business Updates In March, Aptinyx completed an...

      March 30 2023
      Business Wire

      Aptinyx Reports Results from Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson's Disease and Dementia with Lewy Bodies and Provides Pipeline and Corporate Update

      NYX-458 did not demonstrate sufficient efficacy in the Phase 2 study to support further development by Aptinyx The company will undertake cost-cutting measures and explore strategic...

      February 27 2023
      Business Wire

      Aptinyx to Present at the SVB Securities Global Biopharma Conference

      Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that Andy...

      January 31 2023
      Business Wire

      Preclinical Data from Aptinyx’s NMDA Receptor Modulators to be Presented at the 52nd Annual Meeting of the Society for Neuroscience

      Aptinyx Inc. (NASDAQ:APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced upcoming poster...

      November 10 2022
      Business Wire

      Aptinyx Reports Third Quarter 2022 Financial Results and Recent Highlights

      Company expects to report results from Phase 2 study of NYX-458 in cognitive impairment in 1Q 2023 $5.6 million NIH grant finalized for research and development of NYX-783 in opioid use...

      November 08 2022
      Business Wire

      Clinical Evaluation of Aptinyx's NYX-783 for Treatment of Opioid Use Disorder to Be Funded by $5.6 Million NIH Grant

      NIH HEAL Initiative grant, administered by NIDA, funds preclinical and clinical studies of NYX-783 in opioid use disorder Preclinical studies demonstrate NYX-783 has promising activity and...

      November 03 2022
      Business Wire

      Aptinyx to Report Third Quarter 2022 Financial Results on Tuesday, November 8, 2022

      Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and nervous system disorders, today announced that the...

      October 18 2022
      Business Wire

      Aptinyx Completes Enrollment in Phase 2 Study of NYX-458 in Cognitive Impairment Associated with Parkinson’s Disease and Dementia with Lewy Bodies

      Results from the Phase 2 study are expected in 1Q 2023 Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain and...

      August 25 2022
      Business Wire

      Aptinyx Reports Results from Phase 2b Study of NYX-2925 in Fibromyalgia

      NYX-2925 did not achieve the primary endpoint of the study Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of brain...

      August 12 2022
      Business Wire
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      1000.0610.0610.06100CS
      4000.0610.0610.06100CS
      12000.0610.0610.06100CS
      26000.0610.0610.06100CS
      52000.0610.0610.06100CS
      156-2.349-97.4688796682.413.75990.0615101710.40860273CS
      260-3.749-98.39895013123.816.470.0615328461.7708093CS

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      LASELaser Photonics Corporation
      $ 18.8671
      (81.24%)
      		13.54M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M
      NVVENuvve Holding Corporation
      $ 6.68
      (70.41%)
      		31.34M
      UXINUxin Ltd
      $ 2.42
      (52.68%)
      		18.24M
      ELABElevai Labs Inc
      $ 0.10545
      (-62.34%)
      		23.66M
      ADTXAditxt Inc
      $ 0.262
      (-31.52%)
      		3.17M
      FRGTFreight Technologies Inc
      $ 0.081
      (-28.82%)
      		26.36M
      ANEBAnebulo Pharmaceuticals Inc
      $ 2.23
      (-27.60%)
      		113.78k
      STSSSharps Technology Inc
      $ 0.1722
      (-27.06%)
      		2.28M
      XPONExpion360 Inc
      $ 0.1144
      (34.91%)
      		432.21M
      NVDANVIDIA Corporation
      $ 116.26
      (0.22%)
      		206.23M
      INTCIntel Corporation
      $ 22.56
      (3.30%)
      		184.44M
      KAVLKaival Brands Innovations Group Inc
      $ 1.33
      (129.71%)
      		182.46M
      TGLTreasure Global Inc
      $ 1.18
      (73.45%)
      		139.95M

      APTX Discussion

      View Posts
      Renee Renee 9 months ago
      APTX: effective Jan. 2,2024: Company Dissolved/Final Liquidation.

      FINRA will delete the symbol:

      https://otce.finra.org/otce/dailyList?viewType=Deletions
      👍️0
      Renee Renee 1 year ago
      APTX delisted from the Nasdaq to the OTC:

      https://otce.finra.org/otce/dailyList?viewType=Additions
      👍️0
      surf1944 surf1944 1 year ago
      https://stockcharts.com/h-sc/ui?s=aptx&p=D&yr=0&mn=6&dy=0&id=p38090673899

      https://www.barchart.com/stocks/quotes/aptx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

      https://www.barchart.com/stocks/quotes/aptx/opinion

      Moving again!
      👍️0
      surf1944 surf1944 1 year ago
      https://stockcharts.com/h-sc/ui?s=aptx&p=D&yr=0&mn=6&dy=0&id=p38090673899

      https://www.barchart.com/stocks/quotes/aptx/technical-chart?plot=CANDLE&volume=total&data=DO&density=ML&pricesOn=1&asPctChange=0&logscale=0&indicators=ACCUM;SMA(20);SMA(50);SMA(100);SMA(200);CHKMF(20)&sym=SYSX&grid=1&height=210&studyheight=100

      https://www.barchart.com/stocks/quotes/aptx/opinion
      👍️ 1
      glenn1919 glenn1919 2 years ago
      APTX.............................https://stockcharts.com/h-sc/ui?s=APTX&p=W&b=5&g=0&id=p86431144783
      👍️0
      bella99 bella99 2 years ago
      Looks like offerings going through Now?????????
      👍️0
      BeamMeUpScotty BeamMeUpScotty 2 years ago
      $50m+ cash in hand so no need for any offerings any time soon. Huge gaps to the up side!
      👍️0
      BeamMeUpScotty BeamMeUpScotty 2 years ago
      Also has huge institutional investors. Takes up two pages! See the link.

      Scroll all the way down

      https://whalewisdom.com/stock/aptx

      This patent is for a treatment for depression which unfortunately is suffered by more and more people every year so the potential market is huge.

      Link to the patent.

      https://data.epo.org/publication-server/pdf-document?pn=3490992&ki=B1&cc=EP


      👍️0
      MASTERULTRA MASTERULTRA 2 years ago
      NO SHHH... THIS SHIT IS BLOWING UP AND I AM SURPRISED...
      👍️0
      MASTERULTRA MASTERULTRA 2 years ago
      Stocktwit blowing this shit up. Over 10mil in buys AH. HOLYSHIT...
      👍️0
      BeamMeUpScotty BeamMeUpScotty 2 years ago
      Dude if you look at the “tape” there’s a lot of buys still coming in at high of the day after hours!
      👍️0
      limer814 limer814 2 years ago
      Ok shhhhhh
      👍️0
      THEMASTERS_SON THEMASTERS_SON 2 years ago
      Shhhhh…keep it quiet til AM!!!
      👍️0
      willlbone willlbone 2 years ago
      Lowered my bid
      to 10 cents.
      👍️0
      mauiguy2 mauiguy2 4 years ago
      Good day yesterday. Any reason for it?
      👍️0
      Moneta Man Moneta Man 4 years ago
      It's one of my favorite quotes from Warren Buffett, the world's most famous value investor: "Price is what you pay; value is what you get." Get ready to get a whole lot of value with APTX going forward. This stock/company is rich with potential!
      👍️0
      Moneta Man Moneta Man 4 years ago
      Status of each clinical study can be found here... https://www.aptinyx.com/clinical-studies/
      👍️0
      Moneta Man Moneta Man 4 years ago
      https://www.smarteranalyst.com/new-blurbs/aptinyx-aptx-receives-a-buy-from-h-c-wainwright/?mod=mw_quote_news
      👍️0
      Moneta Man Moneta Man 4 years ago
      Hoping to learn more about their clinical trials in progress today after market close...
      https://finance.yahoo.com/news/aptinyx-inc-host-earnings-call-201500829.html
      👍️0
      Moneta Man Moneta Man 4 years ago
      Here's a link to the NYX-783 study in Phase II trials:
      https://clinicaltrials.gov/ct2/show/NCT04044664?term=NYX-783&rank=1
      👍️0
      Moneta Man Moneta Man 4 years ago
      Here's a link to the NYX-783 study in Phase II trials:
      https://clinicaltrials.gov/ct2/show/NCT04044664?term=NYX-783&rank=1
      👍️0
      Moneta Man Moneta Man 4 years ago
      Aptinyx is advancing a leading portfolio of novel CNS therapies - pretty exciting. Here's a link to current Phase II trials in the pipeline:
      https://www.aptinyx.com/pipeline/
      👍️0
      Moneta Man Moneta Man 4 years ago
      Aptinyx is advancing a leading portfolio of novel CNS therapies - pretty exciting. Here's a link to current Phase II trials in the pipeline:
      https://www.aptinyx.com/pipeline/
      👍️0
      ClayTrader ClayTrader 4 years ago
      * * $APTX Video Chart 10-20-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      crudeoil24 crudeoil24 4 years ago
      APTX > Conference Call Information:

      scheduled for 8:30 a.m. ET

      To access the live conference call and webcast presentation, please dial (866) 939-3921 (U.S. Toll Free) or (678) 302-3550 (U.S. Toll) and refer to conference ID 49992933. A live audio and webcast presentation will be available on the Investors & Media section of Aptinyx's website at https://ir.aptinyx.com. A replay of the webcast will be archived on Aptinyx's website for 30 days following the event.
      👍️0
      crudeoil24 crudeoil24 4 years ago
      New price targets, possibly above $10.00 in the forecast.

      Aptinyx started at outperform with $7 stock price target at Wedbush
      8:40 am ET September 12, 2019 (MarketWatch)
      Share
      Print
      (END) Dow Jones Newswires
      👍️0
      realfast95 realfast95 4 years ago
      bam too da moon
      👍️0
      ClayTrader ClayTrader 5 years ago
      * * $APTX Video Chart 01-17-2020 * *

      Link to Video - click here to watch the technical chart video

      👍️0
      crudeoil24 crudeoil24 5 years ago
      Aptinyx started at outperform with $7 stock price target at Wedbush
      8:40 am ET September 12, 2019 (MarketWatch)
      Share
      Print
      (END) Dow Jones Newswires

      September 12, 2019 08:40 ET (12:40 GMT)

      Copyright (c) 2019 Dow Jones & Company, Inc.
      👍️0
      crudeoil24 crudeoil24 5 years ago
      APTX > Aptinyx Inc. is a clinical-stage biopharmaceutical company. The Company discovers and develops therapies for disorders of the brain and nervous system. The Company has a platform for discovering compounds that work through a mechanism, which includes modulation of the N-methyl-D-aspartate (NMDA) receptor to develop pathways involved with nerve cell communication. The Company's compounds are effective on disease models including, depression, neuropathic pain, migraine, traumatic brain injury and age-induced learning impairment. The Company's compounds facilitate receptor activation without over-activating the receptor. The Company’s lead product candidate is NYX-2925, a treatment for the painful diabetic peripheral neuropathy. It is also developing NYX-783 for the treatment of post-traumatic stress disorder and NYX-458 for Parkinson’s disease cognitive impairment. The Company in partnership with Allergan plc, develops AGN-241751 for major depressive disorder indications.
      👍️0

      Your Recent History

      NASDAQ
      APTX
      Aptinyx
      Delayed Upgrade Clock